Secondary Central Nervous System Lymphoma Clinical Trial
Official title:
A Phase II, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of ICP-022 in Patients With Recurrent/Refractory Central Nervous System Lymphoma and Recurrent/Refractory Secondary Central Nervous System Lymphoma
Verified date | October 2022 |
Source | Beijing InnoCare Pharma Tech Co., Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The phase II clinical study is to investigate the safety, tolerability, efficacy and pharmacokinetics of ICP-022.
Status | Active, not recruiting |
Enrollment | 61 |
Est. completion date | December 31, 2023 |
Est. primary completion date | December 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Key Inclusion Criteria: 1. Men and women = 18, and =75 years of age 2. Histologically documented PCNSL, or histologically documented systemic diffuse large B-cell lymphoma (DLBCL) for SCNSL. 3. Subjects with refractory or relapsed disease, one prior CNS directed therapy, and = 4 systemic treatments. 4. ECOG performance status of 0-2 5. Able to provide signed written informed consent Key Exclusion Criteria: 1. Patients with SCNSL actively receiving treatment for extra-CNS disease are excluded 2. T-cell lymphoma. 3. Patient requires more than 8 mg of dexamethasone daily or the equivalent. 4. Non-hematological toxicity must recover to = Grade 1 from prior anti-cancer therapy (except for alopecia) 5. Known active infection with HBV, HCV or HIV. Note: Other protocol defined Inclusion/Exclusion criteria may apply. |
Country | Name | City | State |
---|---|---|---|
China | Beijing Cancer Hospital | Beijing | Beijing |
China | Beijing Tiantan Hospital affiliated to Capital Medical University | Beijing | Beijing |
China | Capital Medical University Xuanwu Hospital | Beijing | Beijing |
China | Guangdong General Hospital | Guangzhou | Guangdong |
China | Huashan Hospital affiliated to Fudan University | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Beijing InnoCare Pharma Tech Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The efficacy measured by overall response rate (ORR) | Cycle 1-6 once every 2 cycles; more than 6 cycles once every 3 cycles. Each cycle is 28 days | ||
Secondary | The occurrence of adverse events and serious adverse events | The safety of ICP-022 measured by the occurrence of adverse events and serious adverse events according to NCI-CTCAE 4.03 grading criteria | every cycle, first cycle every week. Each cycle is 28 days | |
Secondary | The efficacy measured by progression free survival (PFS) | cycle 1-6 once every 2 cycles; more than 6 cycles once every 3 cycles. Each cycle is 28 days | ||
Secondary | The efficacy measured by duration of response (DOR) | cycle 1-6 once every 2 cycles; monre than 6 cycles once every 3 cycles. Each cycle is 28 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04457869 -
A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL)
|
Phase 2 | |
Recruiting |
NCT05351593 -
Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03964090 -
Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)
|
Phase 2 | |
Recruiting |
NCT05011045 -
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
|
||
Recruiting |
NCT05256641 -
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05398224 -
R-MTX-zanbrutinib in Secondary CNS Lymphoma
|
Phase 2 | |
Recruiting |
NCT05485753 -
A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
|
Phase 1/Phase 2 | |
Recruiting |
NCT05681195 -
Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
|
Phase 2 |